PALO ALTO, Calif. and
TORONTO, Sept. 3, 2020 /PRNewswire/
-- Inpixon® (Nasdaq: INPX), a leading indoor
data company that delivers Indoor Intelligence™ solutions, today
announced that it has executed contracts to deploy its Indoor
Intelligence solutions for Privée Clinics' flagship cognitive
wellness clinic located in the atrium of the Conrad, Miami, hotel. The contracted solution includes
Inpixon Pod Wi-Fi sensors, Inpixon Workplace Readiness Dashboards
and Inpixon Mapping with the installation to be completed prior to
the November 16, 2020, clinic grand
opening.
Privée Clinics will offer personalized, high-end wellness
services intended to enhance cognitive performance and physical
health and beauty as well as to reduce stress, improve sleep and
boost immunity against viral infections such as COVID-19. By
decreasing the effects of stress on the brain through advanced
technology oxygenation techniques and nutritional supplementation,
Privée Clinics intends to help its clients slow the ageing process,
particularly as it affects the brain. Privée Clinics was founded by
the renowned Bankole Johnson, MD,
founder and chief medical officer of Adial Pharmaceuticals.
Inpixon's Mapping and near real-time analytics will help Privée
Clinics with their efforts to provide world-class service to their
clientele by showing trends and changes in people flow and density
by zones using device positioning and dwell times. Inpixon's
Workplace Readiness dashboard will provide a comprehensive
viewpoint of the facility that can assist the doctors and staff
members with a dynamic, multidimensional map of the clinic,
including key insights on zone health based on area occupancy
density, to support new safety protocols and regulations, along
with the flexibility to address future indoor location-based use
cases.
"Privée Clinics is delighted to implement Inpixon Indoor
Intelligence technologies into our clinics to create what we
believe is the world's first anti-COVID-19 model clinic system,"
commented Dr. Johnson, Founder, Executive Chairman and CEO of
Privée Clinics. "As a leading physician, I was impressed by the
capabilities of Inpixon's offering and the fact they are already
trusted by many notable healthcare facilities, commercial
enterprises and the U.S. government. Inpixon's technology will
assist with efficient client processing through the clinic and
rapid decontamination of areas that need it most, delivering a
safer, tailored and world-class approach to bespoke health
care."
"Inpixon is excited to be included as a fundamental element of
the new Privée Clinics offering," said Soumya Das, COO of Inpixon. "They are striving
to establish a new standard of care during this pandemic situation
and beyond, and setting a high bar for all doctors' offices and
clinics to follow. We're proud to play such an integral role in
this important endeavor."
About Inpixon
Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™
company that specializes in capturing, interpreting and giving
context to indoor data so it can be translated into actionable
intelligence. The company's Indoor Intelligence platform ingests
diverse data from IoT, third-party and proprietary sensors designed
to detect and position active cellular, Wi-Fi, UWB and Bluetooth
devices. Paired with a high-performance data analytics engine,
patented algorithms, and advanced mapping technology, Inpixon's
solutions are leveraged by a multitude of industries to do good
with indoor data. This multidisciplinary depiction of indoor data
enables users to increase revenue, decrease costs, and enhance
safety. Inpixon customers can boldly take advantage of location
awareness, analytics, sensor fusion and the Internet of Things
(IoT) to uncover the untold stories of the indoors. For the latest
insights, follow Inpixon on LinkedIn, Twitter, and
visit inpixon.com.
Safe Harbor Statement
All statements in this release that are not based on
historical fact are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and the
provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. While management has based any forward-looking statements
included in this release on its current expectations, the
information on which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties and other factors, many of which are outside of the
control of Inpixon and its subsidiaries, which could cause actual
results to materially differ from such statements. Such risks,
uncertainties, and other factors include, but are not limited to,
the fluctuation of economic conditions, the impact of COVID-19 on
Inpixon's results of operations, the performance of management and
employees, the regulatory landscape as it relates to privacy
regulations and their applicability to Inpixon's technology,
Inpixon's ability to maintain compliance with Nasdaq's minimum bid
price requirement and other continued listing requirements,
including during a panel monitoring period ending on February 5, 2021, the ability to obtain
financing, competition, general economic conditions and other
factors that are detailed in Inpixon's periodic and current reports
available for review at sec.gov. Furthermore, Inpixon operates in a
highly competitive and rapidly changing environment where new and
unanticipated risks may arise. Accordingly, investors should not
place any reliance on forward-looking statements as a prediction of
actual results. Inpixon disclaims any intention to, and undertakes
no obligation to, update or revise forward-looking
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/inpixon-workplace-readiness-solution-selected-by-privee-clinics-to-safeguard-the-health-and-welfare-of-clients-301123686.html
SOURCE Inpixon